IrelandUnited KingdomFranceSwitzerlandAustriaGermanySwitzerlandItalySwitzerlandSpainFranceChinaGermanySpainItalyAustriaSwitzerland

ImmuCyst 81mg

BCG immunotherapy

ImmuCyst is indicated for intravesical use in the treatment and prophylaxis of non-muscle invasive bladder cancer. It is supplied as a freeze-dried powder preparation made from the Connaught substrain of Bacillus Calmette-Guérin (BCG), which is an attenuated strain of Mycobacterium bovis.

Strength: 81mg

Pack size: 1 x 5ml vial

PIP code : 286-0203

Legal status: POM

Summary of Products Characteristics Patient information Leaflet

Always read the label

Adverse events (side effects) thought to have been caused by one of our products should be reported to the MHRA via their yellow card scheme and to Alliance’s Pharmacovigilance team. Click here to submit a report